BridgeBio Oncology Therapeutics develops oral cancer drug candidates that target KRAS and PI3Kα signaling. It last closed at $1.81 on Nov 20, down 2.69% on the day. The next earnings report for BBOT is expected around Thu, Mar 4, 2027, after the close. For the quarter ended Sep 2026, BBOT reported EPS of -$0.43. Over its last 5 reports the stock moved an average of 5.3% the session after earnings. Over the last 12 months BBOT insiders bought $0 of stock on the open market and sold $4K, according to SEC Form 4 filings.
AI Auto Pilots
Is BBOT in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold BBOT.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on BBOTStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
BBOT · as of the Nov 20 close · updated each morning
Downtrend, oversold
The stock is 26% below its 20 day and 73% below its 50 day average. It is 309% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 29), oversold. The nearest support is the 52 week low at $1.78, and the nearest resistance the Pivot at $1.84.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 14.0%/day
Key levels
$14.8752 week high+721.5%
$7.40200 day average+308.8%
$5.89100 day average+225.4%
$3.1450 day average+73.5%
$2.68Swing high (Nov 12)+48.1%
$2.2820 day average+26.0%
$1.91Pivot R1+5.5%
$1.84Pivot+1.7%
$1.81Last close
$1.7852 week low−1.7%
$1.75Pivot S1−3.3%
Indicators
RSI (14)
28.93
Oversold below 30
Oversold
MACD
-0.42
Above its signal line
Bullish
Stochastic
4.1
Near the bottom of its range
Oversold
ADX (14)
49.1
Strong downtrend
Williams %R
-97.2
Oversold below −80, overbought above −20
Oversold
CCI (20)
-126.1
Oversold below −100, overbought above 100
Oversold
Rate of change
−11.3%
Change over 10 sessions
Bearish
ATR (14)
$0.25
Typical daily range, 14.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling, oversold
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchOversold
VolatilityHigh, 51.9%/day
Key levels
$14.8752 week high+721.5%
$7.40200 day average+308.8%
$5.89100 day average+225.4%
$3.1450 day average+73.5%
$2.68Swing high (Nov 12)+48.1%
$2.2820 day average+26.0%
$1.91Pivot R1+5.5%
$1.84Pivot+1.7%
$1.81Last close
$1.7852 week low−1.7%
$1.75Pivot S1−3.3%
Indicators
RSI (14)
21.30
Oversold below 30
Oversold
MACD
-1.87
Below its signal line
Bearish
Stochastic
1.0
Near the bottom of its range
Oversold
ADX (14)
37.8
Trending down
Williams %R
-99.7
Oversold below −80, overbought above −20
Oversold
CCI (20)
-96.1
Oversold below −100, overbought above 100
Neutral
Rate of change
−63.4%
Change over 10 sessions
Bearish
ATR (14)
$0.94
Typical daily range, 51.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for BBOT
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how BBOT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for BBOTHow many large options trades hit BBOT, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in BBOT in the last 90 days.
From SEC Form 4 filings by BBOT's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BBOT is in one of them and how their past BBOT trades turned out.
BridgeBio Oncology Therapeutics is a biotechnology company based in South San Francisco, California, that is developing oral small molecule drugs for cancer. Its pipeline targets KRAS, a protein that is mutated in many cancers, and PI3Kα, a signaling protein that RAS proteins activate. The company is designing its drug candidates for patients with lung, breast, pancreatic and colorectal cancers, and it is testing them in early stage clinical trials.